Karyopharm Therapeutics Inc
F:25K
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Karyopharm Therapeutics Inc
F:25K
|
US |
|
Delta Technologies Nyrt
F:E8E4
|
HU |
|
C
|
Chilled & Frozen Logistics Holdings Co Ltd
TSE:9099
|
JP |
|
8
|
8x8 Inc
F:EGT
|
US |
|
F
|
FirstGroup PLC
XBER:FGR
|
UK |
|
MultiChoice Group Ltd
F:30R
|
ZA |
|
Covivio SA
F:F5D
|
FR |
|
Pactiv Evergreen Inc
F:PEG
|
US |
|
P
|
Penumbra Inc
F:0P8
|
US |
|
Akzo Nobel NV
F:AKUP
|
NL |
|
Entech SA
F:0AS
|
FR |
|
Sequana Medical NV
F:2SE
|
BE |
Wall St Price Targets
25K Price Targets Summary
Karyopharm Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 25K is 6.69 EUR with a low forecast of 3.46 EUR and a high forecast of 8.23 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 25K's stock price target?
Price Target
6.69
EUR
According to Wall Street analysts, the average 1-year price target for 25K is 6.69 EUR with a low forecast of 3.46 EUR and a high forecast of 8.23 EUR.
What is the Revenue forecast for Karyopharm Therapeutics Inc?
Projected CAGR
24%
Over the last 13 years, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 24%.
What is the Gross Profit forecast for Karyopharm Therapeutics Inc?
Projected CAGR
15%
The compound annual growth rate for Gross Profit over the next 3 years is 15%.
